ANRS COV33 Coverage Africa
A sub-study of the Anticov trial: Early treatment of vulnerable people with non-severe SARS-CoV-2 infection: a randomised multi-arm, multi-stage (MAMS) trial to assess the efficacy of several specific treatments in reducing the risk of clinical worsening or death in sub-Saharan Africa
Last updated on 27 February 2024
Primary objective
To assess the efficacy of several specific treatments in preventing the progression of a documented SARS-CoV-2 infection towards severity (defined as the need for oxygen or death) in adults aged 40 years and over or adults with co-morbidities (obesity or known hypertension or diabetes) in sub-Saharan Africa.
Theme
Covid-19
Status
Ongoing
Population
Adults
Samples
Nasopharyngeal swabs, saliva, blood
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr
You are participating or have participated in this study
On the form above, you will find information on the ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.
If you would like to find out more about your participation in a clinical study, please see the section below.
Visit the participant area